Cognition and communication dysfunctions in early-onset schizophrenia: Effect of risperidone

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 39, Issue 2, 2012, Pages 348-354

  Remberk, Barbara ^a   Namysłowska, Irena ^a   Rybakowski, Filip ^a  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Adolescent; Antipsychotics; Cognitive impairment; Formal thought disorder; Psychosis

Indexed keywords

RISPERIDONE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; COMMUNICATION DISORDER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; EXECUTIVE FUNCTION; FEMALE; FLUENCY DISORDER; FORMAL THOUGHT DISORDER; GENERAL CONDITION; HUMAN; MALE; NEGATIVE SYNDROME; ONSET AGE; OUTCOME ASSESSMENT; SCHIZOPHRENIA; THOUGHT DISORDER; VERBAL COMMUNICATION; WORKING MEMORY;

ADOLESCENT; ADOLESCENT BEHAVIOR; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; COMMUNICATION DISORDERS; EARLY MEDICAL INTERVENTION; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84867000795     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.07.007     Document Type: Article

References (69)

1. Amminger G.P., Henry L.P., Harrigan S.M., Harris M.G., Alvarez-Jimenez M., Herrman H., et al. Outcome in early-onset schizophrenia revisited: findings from the Early Psychosis Prevention and Intervention Centre long-term follow-up study. Schizophr Res 2011, 131:112-119.
2. Andreasen N.C. Thought, language and communication disorders II. Diagnostic significance. Arch Gen Psychiatry 1979, 36:1325-1331.
3. Andreasen N.C. Scale for the assessment of thought, language, and communication (TLC). Schizophr Bull 1986, 12:473-482.
4. Banaschewski T., Schulz E., Martin M., Remschmidt H. Cognitive functions and psychopathological symptoms in early-onset schizophrenia. Eur Child Adolesc Psychiatry 2000, 9:11-20.
5. Bearden C.E., Wu K.N., Caplan R., Cannon T.D. Thought disorder and communication deviance as predictors of outcome in youth at clinical high risk for psychosis. J Am Acad Child Adolesc Psychiatry 2011, 50:669-680.
6. Bokat C.E., Goldberg T.E. Letter and category fluency in schizophrenic patients: a meta-analysis. Schizophr Res 2003, 64:73-78.
7. Bowie C.R., Harvey P.D. Communication abnormalities predict functional outcomes in chronic schizophrenia: differential associations with social and adaptive functions. Schizophr Res 2008, 240-247.
8. Brekke J.S., Hoe M., Green M.F. Neurocognitive change, functional change and service intensity during community-based psychosocial rehabilitation for schizophrenia. Psychol Med 2009, 39:1637-1647.
9. Brzezinski J., Gaul M., Hornowska E., Jaworowska A., Machowski A., Zakrzewska M. Wechsler Adult Intelligence Scale Revised (WAIS-R). Manual 1996, Pracownia Testów Psychologicznych Polskiego Towarzystwa Psychologicznego, Warsaw.
10. Czernikiewicz A. Linguistic dimension of chronic schizophrenia 1998, Akademia Medyczna w Lublinie, Lublin. 1st ed.
11. Docherty N.M., Cohen A.S., Nienow T.M., Dinzeo T.J., Dangelmaier R.E. Stability of formal thought disorder and referential communication disturbances in schizophrenia. J Abnorm Psychol 2003, 112:469-475.
12. Erickson W.D., Yellin A.M., Hopwood J.H., Realmuto G.M., Greenberg L.M. The effects of neuroleptics on attention in adolescent schizophrenics. Biol Psychiatry 1984, 19:745-753.
13. Faber G., Smid H.G.O.M., Gool A.R.V., Wunderink L., Wiersma D., van den Bosch R.J. Neurocognition and recovery in first episode psychosis. Psychiatry Res 2011, 188:1-6.
14. Frazier J.A., Giuliano A.J., Johnson J.L., Yakutis L., Youngstron E.A., Breiger D., et al. Nuerocognitive outcomes in the treatment of early-onset schizophrenia spectrum disorders study. J Am Acad Child Adolesc Psychiatry 2012, 51:496-505.
15. Goldberg T.E., Goldman R.S., Burdick K.E., Malhotra A.K., Lencz T., Patel R.C., et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?. Arch Gen Psychiatry 2007, 64:1115-1122.
16. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry 1996, 153:321-330.
17. Green M.F., Bearden C.E., Cannon T.D., Fiske A.P., Hellemann G.S., Horan W.P., et al. Social cognition in schizophrenia, part 1: performance across phase of illness. Schizophr Bull 2011, 10.1093/schbul/sbq171.
18. Guy W. ESDEU assessement manual for psychopharmacology, revised. DHEW pub. no. (ADM) 76-338 1976, National Institute of Mental Health, Rockville, MD.
19. Haas M., Unis A.S., Armenteros J., Copenhaver M.D., Quiroz J.A., Kushner S.F. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 2009, 19:611-621.
20. Haas M., Eerdekens M., Kushner S., Singer J., Augustyns I., Quiroz J.A., et al. Efficacy, safety and tolerability of two risperidone dosing regiments in adolescent schizophrenia: double-blind study. Br J Psychiatry 2009, 194:158-164.
21. Hassan G.A.M., Taha G.R.A. Long term functioning in early onset psychosis: two years prospective follow-up study. Behav Brain Funct 2011, 30:7-28.
22. Heaton R.K., Chelune G.J., Talley J.L., Kay G.G., Curtiss G. Wisconsin card sorting test manual 1993, Psychological Assessment Resources, Odessa, Florida.
23. Hill S.K., Bishop J.R., Palumbo D., Sweeney J.A. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev Neurother 2010, 10:43-57.
24. Holmén A., Juuhl-Langseth M., Thormodsen R., Melle I., Rund B.R. Neuropsychological profile in early-onset schizophrenia-spectrum disorders: measured with the MATRICS battery. Schizophr Bull 2010, 36:852-859.
25. Horan W.P., Green M.F., DeGroot M., Fiske A., Hellemann G., Kee K., et al. Social cognition in schizophrenia, part 2: 12-month stability and prediction of functional outcome in first-episode patients. Schizophr Bull 2011, 10.1093/schbul/sbr001.
26. Houthoofd S.A.M.K., Morrens M., Sabbe B.G.C. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. Clin Ther 2008, 30:1565-1589.
27. Kay S., Fiszbein A., Opler L. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
28. Keefe R.S., Silva S.G., Perkins D.O., Lieberman J.A. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999, 25(2):201-222.
29. Kennedy E., Kumar A., Datta S.S. Antipsychotic medication for childhood-onset schizophrenia. Cochrane Libr 2012, 2. 10.1002/14651858.CD004027.pub2.
30. Kerns J.G., Berenbaum H. Cognitive impairments associated with formal thought disorder in people with schizophrenia. J Abnorm Psychol 2002, 111:211-224.
31. Kim H.S., Shin N.Y., Jang J.H., Kim E., Shim G., Park H.Y., et al. Social cognition and neurocognition as predictors of conversion to psychosis in individuals at ultra-high risk. Schizophr Res 2011, 130:170-175.
32. Kravariti E., Morris R.G., Rabe-Hesketh S., Murray R.M., Frangou S. The Maudsley early-onset schizophrenia study: cognitive function in adolescent-onset schizophrenia. Schizophr Res 2003, 65:95-103.
33. Kurcz I. Polish frequency norms of free associations with 100 words from Kent-Rosanoff list. Stud Psychol 1967, 8:122-127.
34. Levy D.L., Coleman M.J., Sung H., Ji F., Matthysse S., Mendell N.R., et al. The genetic basis of thought disorder and language and communication disturbances in schizophrenia. J Neurolinguist 2010, 23:176-192.
35. Li C.S. Do schizophrenia patients make more perseverative errors than non-perseverative errors in Wisconsin card sorting test? A meta-analytic study. Psychiatry Res 2004, 129:179-190.
36. Lin A., Wood S.J., Nelson B., Brewer W.J., Spiliotacopoulos D., Bruxner A., et al. Neurocognitive predictors of functional outcome two to 13years after identification as ultra-high risk for psychosis. Schizophr Res 2011, 132:1-7.
37. Łobacz P., Mikołajczak-Matyja N. Verbal assosiations in psycholexicology and psycholinguistic onomastics 2002, Sorus, Poznań.
38. Mattai A.K., Hill J.L., Lenroot R.K. Treatment of early-onset schizophrenia. Curr Opin Psychiatry 2010, 23:304-310.
39. McClellan J., Prezbindowski A., Breiger D., McCurry C. Neuropsychological functioning in early onset psychotic disorders. Schizophr Res 2004, 68:21-26.
40. McGurk S.R., Mueser K.T. Cognitive functioning, symptoms, and work in supported employment: a review and heuristic model. Schizophr Res 2004, 70:147-173.
41. Namyslowska I. Thought disorders in schizophrenia before and after pharmacological treatment. Compr Psychiatry 1975, 16:37-42.
42. Neuchterlein K.H., Subotnik K.L., Green M.F., Ventura J., Asarnow R.F., Gitlin M.J., Yee C.M., Gretchen-Doorly, Mintz J. Neurocognitive predictors of work outcome in recent-onset schizophrenia. Schizophr Bull 2011, 37(suppl 2):S33-S40.
43. Nieuwenstein M.R., Aleman A., de Haan E.H. Relationship between symptom dimensions and neurocognitive functioning in schizophrenia: a meta-analysis of WCST and CPT studies Wisconsin Card Sorting Test. Continuous Performance Test. J Psychiatr Res 2001, 35:119-125.
44. Pool D., Bloom W., Mielke D.H., Roniger J.J.J., Gallant D.M. A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Curr Ther 1976, 19:99-104.
45. Purdon S.E., Jones B.D., Stip E., Labelle A., Addington D., David S.R., et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 2000, 57:249-258.
46. Rabinowitz J., Levine S.Z., Häfner H. A population based elaboration of the role of age of onset on the course of schizophrenia. Schizophr Res 2006, 88:96-101.
47. Rajji T.K., Ismail Z., Mulsant B.H. Age at onset and cognition in schizophrenia: meta-analysis. Br J Psychiatry 2009, 195:286-293.
48. Rapoport J.L., Giedd J.N., Gogtay N. Neurodevelopmental model of schizophrenia: update 2012. Mol Psychiatry 2012, 10.1038/mp. 2012.23.
49. Remberk B., Namysłowska I., Rybakowski F. Clinical and cognitive correlates of formal thought disorder in early onset schizophrenia. Neuro Endocrinol Lett 2012, 33:347-355.
50. Remington G., Foussias G., Agid O. Progress in defining optimal treatment outcome in schizophrenia. CNS Drugs 2010, 24:9-20.
51. Remschmidt H. Early-onset schizophrenia as a progressive-deteriorating developmental disorder: evidence from child psychiatry. J Neural Transm 2002, 109:101-117.
52. Rhinewine J.P., Lencz T., Thaden E.P., Cervellione K.L., Burdick K.E., Henderson I., et al. Neurocognitive profile in adolescents with early-onset schizophrenia: clinical correlates. Biol Psychiatry 2005, 58:705-712.
53. Robles O., Zabala A., Bombín I., Parellada M., Moreno D., Ruiz-Sancho A., et al. Cognitive efficacy of quetiapine and olanzapine in early-onset first-episode psychosis. Schizophr Bull 2011, 37:405-415.
54. Rzewuska M. Validity and reliability of the Polish version of the Positive and Negative Syndrome Scale (PANSS). Int J Methods Psychiatr Res 2002, 11:27-32.
55. Schuepbach D., Keshavan M.S., Kmiec J.A., Sweeney J.A. Negative symptom resolution and improvements in specific cognitive deficits after acute treatment in first-episode schizophrenia. Schizophr Res 2002, 53:249-261.
56. Sikich L., Frazier J.A., McClellan J., Findling R.L., Vitiello B., Ritz L., et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008, 165:1420-1431.
57. Sommer R., Witney G., Osmond H. Teaching common associations to schizophrenics. J Abnorm Soc Psychol 1962, 65:58-64.
58. Spaulding W.D., Fleming S.K., Reed D., Sullivan M., Storzbach D., Lam M. Cognitive functioning in schizophrenia: implications for psychiatric rehabilitation. Schizophr Bull 1999, 25:275-289.
59. Spohn H.E., Coyne L., Larson J., Mittleman F., Spray J., Hayes K. Episodic and residual thought pathology in chronic schizophrenics: effect of neuroleptics. Schizophr Bull 1986, 12:394-407.
60. SPSS package v. 18.0 for Windows. Statistical Package for Social Sciences 2009, SPSS Incorporate, USA.
61. Stip E., Chouinard S., Boulay L.J. On the trail of a cognitive enhancer for the treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:219-232.
62. Szöke A., Trandafir A., Dupont M.E., Méary A., Schürhoff F., Leboyer M. Longitudinal studies of cognition in schizophrenia: meta-analysis. Br J Psychiatry 2008, 192:248-257.
63. Ueland T., Øie M., Landrø I.N., Rund B.R. Cognitive functioning in adolescents with schizophrenia spectrum disorders. Psychiatry Res 2004, 126:229-239.
64. Vyas N.S., Gogtay N. Treatment of early onset schizophrenia: recent trends, challenges and future considerations. Front Psychiatry 2012, 10.3389/fpsyt.2012.00029.
65. Vyas N.S., Patel N.H., Puri B.K. Neurobiology and phenotypic expression in early onset schizophrenia. Early Interv Psychiatry 2011, 5:3-14.
66. Wang X., Savage R., Borisov A., Rosenberg J., Woolwine B., Tucker M., et al. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study. J Psychiatr Res 2006, 40:669-676.
67. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005, 8:457-472.
68. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res 2007, 89:211-224.
69. World Health Organization The ICD-10 classification of mental and behavioral disorders. Diagnostic criteria for research 1993, World Health Organization, Geneva.